Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nektar Therapeutics, a biopharmaceutical company taht develops new therapeutics based on its PEGylation and advanced polymer conjugation technology platforms, has reported total revenues of $45.31m for the fourth quarter ended 31 December 2010, compared to $39.01m for the same period in 2009.
Subscribe to our email newsletter
Nektar has posted a net loss of $22.58m for the fourth quarter of 2010, compared to net loss $7.68m for the same period in 2009.
The company’s loss from operations was $20.54m, compared to $5.5m for the same period in 2009.
For the full-year ended 31 December 2010, the company posted a net loss of 37.93m, compared to $102.52m for the same period in 2009.
Total revenues for the full-year of 2010 were $159.04m, compared to $71.93m for the same period in 2009.
The company’s loss from operations was $28.26m, compared to $95.13m in the same period of 2009.
Nektar president and CEO Howard Robin said their lead oncology program, NKTR-102, demonstrated positive results in Phase 2 studies in both ovarian and breast cancers, and we plan to move into Phase 3 in 2011.
"NKTR-118, partnered with AstraZeneca, and NKTR-061, partnered with Bayer, are both planned to move into Phase 3 this year as well," Robin said.
"Nektar’s research pipeline is on track to deliver one new clinical candidate each year, and we are looking forward to starting Phase 1 clinical studies of NKTR-181, our novel opioid analgesic, this month."